Smit E F, Carney D N, Harford P, Sleijfer D T, Postmus P E
Department of Pulmonary Diseases, State University Hospital Groningen, The Netherlands.
Thorax. 1989 Aug;44(8):631-3. doi: 10.1136/thx.44.8.631.
Thirty five previously untreated patients with small cell lung cancer older than 70 years were treated with oral etoposide (800 mg/m2 over five consecutive days) every four weeks. Twenty two patients had extensive disease and 13 limited disease. The overall response rate was 71%. The median survival for patients with limited diseases was 16 (range 6-32) months and for patients with extensive disease nine (range 4-17) months. There was mild haematological toxicity and alopecia but no major toxicity. It is concluded that etoposide in this dose regimen is an effective and well tolerated treatment for elderly patients with small cell lung cancer.
35名年龄超过70岁、此前未接受过治疗的小细胞肺癌患者接受了口服依托泊苷治疗（连续5天，800mg/m²），每4周进行一次。22例患者为广泛期疾病，13例为局限期疾病。总缓解率为71%。局限期疾病患者的中位生存期为16个月（范围6 - 32个月），广泛期疾病患者为9个月（范围4 - 17个月）。有轻度血液学毒性和脱发，但无严重毒性。结论是，这种剂量方案的依托泊苷对老年小细胞肺癌患者是一种有效且耐受性良好的治疗方法。
